{"product_id":"exactsciences-marketing-mix","title":"Exact Sciences Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Exact Sciences aligns product innovation, tiered pricing, targeted distribution, and evidence-based promotion to lead in molecular diagnostics; the preview highlights key tactics, but the full 4P's Marketing Mix delivers actionable, presentation-ready insights and real-world data to replicate their success—get the editable report to save time and sharpen strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCologuard Plus Next-Generation Screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCologuard Plus, launched Q1 2025, is Exact Sciences’ flagship non-invasive colorectal screening test with novel biomarkers and lab upgrades that cut false positives by ~40% and boost sensitivity versus prior Cologuard; clinical data show sensitivity \u0026gt;94% for CRC and advanced adenomas. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncotype DX Precision Oncology Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncotype DX portfolio is the global standard genomic test for breast, colon, and prostate cancers, guiding recurrence risk and chemotherapy benefit to reduce over‑treatment. As of late 2025, over 2 million patients tested worldwide, driving an estimated $1.1 billion cumulative revenue for Exact Sciences through 2025. Clinicians use these assays to tailor therapy to tumor biology, improving decisions and lowering unnecessary chemo use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncodetect Molecular Residual Disease Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLaunched April 2025, Oncodetect is Exact Sciences’ tumor-informed molecular residual disease (MRD) test that detects circulating tumor DNA (ctDNA) to identify residual cancer and monitor recurrence in solid tumors.\u003c\/p\u003e\n\u003cp\u003eClinical data show ctDNA detection up to two years earlier than imaging, enabling proactive therapy changes; early intervention studies report up to 30% improved relapse-free survival in select cohorts.\u003c\/p\u003e\n\u003cp\u003eOncodetect expands Exact Sciences into post-diagnosis monitoring, targeting a market estimated at $6–8 billion by 2030 and complementing its screening portfolio to drive recurring revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCancerguard Multi-Cancer Early Detection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExact Sciences launched Cancerguard in H2 2025 as a laboratory-developed test that detects multiple cancers from one blood draw, using DNA, protein, and methylation biomarkers to flag hard-to-detect cancers like pancreatic and ovarian.\u003c\/p\u003e\n\u003cp\u003eThe move targets the $12–15B global MCED market (2025 estimates) and aligns with population-screening initiatives; Exact Sciences projected incremental revenue of $150–250M by 2027 from Cancerguard assays in clinical channels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-biomarker LDT; single blood draw\u003c\/li\u003e\n\u003cli\u003eTargets pancreatic, ovarian, other late-stage cancers\u003c\/li\u003e\n\u003cli\u003eEntered H2 2025; aims at population screening\u003c\/li\u003e\n\u003cli\u003eMCED market size ~$12–15B in 2025\u003c\/li\u003e\n\u003cli\u003eProj. $150–250M added revenue by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncoExTra Comprehensive Tumor Profiling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncoExTra Comprehensive Tumor Profiling uses whole-exome and whole-transcriptome sequencing to match advanced\/metastatic cancer patients to targeted therapies or clinical trials, supporting precision medicine and Exact Sciences’ role across the cancer care continuum.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Exact Sciences reported oncology services revenue growth of ~12% year-over-year to $1.8B; OncoExTra’s deep profiling increases actionable alteration detection by up to 35% versus panel tests, improving match rates for trials and drugs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eComprehensive genomic + transcriptomic data\u003c\/li\u003e\n\u003cli\u003eTargets late-stage patients for therapies\/trials\u003c\/li\u003e\n\u003cli\u003e~35% higher actionable findings vs panels\u003c\/li\u003e\n\u003cli\u003eContributes to Exact Sciences’ $1.8B oncology services (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExact Sciences 2025: Multi‑product oncology push—Cologuard Plus, Oncotype DX, Oncodetect, Cancerguard\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExact Sciences’ product suite (2025): Cologuard Plus (Q1 2025) CRC screening; Oncotype DX (2M tests, ~$1.1B cumulative revenue through 2025); Oncodetect (Apr 2025) MRD ctDNA; Cancerguard (H2 2025) MCED targeting $12–15B market; OncoExTra profiling (adds ~35% actionable findings). Oncology services revenue $1.8B in 2025, +12% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eLaunch\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard Plus\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eCRC sensitivity \u0026gt;94%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotype DX\u003c\/td\u003e\n\u003ctd\u003eEstablished\u003c\/td\u003e\n\u003ctd\u003e2M tests, $1.1B cum. rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncodetect\u003c\/td\u003e\n\u003ctd\u003eApr 2025\u003c\/td\u003e\n\u003ctd\u003eMRD detection up to 2 yrs earlier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancerguard\u003c\/td\u003e\n\u003ctd\u003eH2 2025\u003c\/td\u003e\n\u003ctd\u003eMCED market $12–15B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncoExTra\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003e+35% actionable findings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Exact Sciences’ Product, Price, Place, and Promotion strategies—grounded in real brand practices and competitive context—ideal for managers, consultants, and marketers needing a ready-to-use, professionally structured marketing brief for reports, presentations, or strategy work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Exact Sciences’ Product, Price, Place and Promotion into a concise, leadership-ready snapshot that’s perfect for meetings, decks, or rapid strategic alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Patient Home Collection Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExact Sciences ships Cologuard kits directly to patients, removing initial clinic visits and enabling at-home stool collection; in 2024 the company reported over 1.3 million kits shipped, driving reach beyond traditional colonoscopy pathways.\u003c\/p\u003e\n\u003cp\u003ePatients return samples via prepaid mail to centralized, high-throughput labs in Madison, Wisconsin, where automated processing scales volume and cuts per-test costs; Exact Sciences reported lab capacity exceeding 2 million tests annually in 2024.\u003c\/p\u003e\n\u003cp\u003eThis decentralized model boosts convenience and uptake: peer-reviewed studies and company data show screening compliance rates for Cologuard near 68% versus 38% for mailed FIT tests, helping increase early detection and potentially reduce downstream costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep Integration with EHR Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpexact sciences has built mission-critical placement in clinician workflows by integrating with major ehrs such as epic and veradigm enabling ordering results inside native charts.\u003e\n\u003cpby late adoption of the diagnostic ordering and results network cut new clinic implementation from months to days lowering go-live time by\u003e\n\u003cpthis digital placement serves over providers who can order and receive exact tests in their ehr cutting admin steps reducing result-entry errors.\u003e\n\u003c\/pthis\u003e\u003c\/pby\u003e\u003c\/pexact\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Precision Oncology Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExact Sciences distributes Oncotype DX and therapy-selection tests in over 90 countries, reaching an addressable market spanning roughly 1.5 billion people across Europe and Asia as of 2025; international revenue contributed about 14% of total revenue in 2024 ($281M of $2.01B). \u003c\/p\u003e\n\u003cp\u003eSpecialized cold-chain logistics and partnerships with regional labs cut tissue-sample degradation risk to under 2% and shorten turnaround by ~24 hours, helping the company scale into markets where precision oncology demand is growing at ~11% CAGR through 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbbott Integration and Subsidiary Status\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing Abbott’s definitive agreement to acquire Exact Sciences in November 2025, Exact’s tests are being folded into Abbott’s diagnostics network, a footprint supporting over $12 billion in annual diagnostics revenue and distribution to 160+ countries; deal expected to close in early 2026.\u003c\/p\u003e\n\u003cp\u003eThis integration gives Exact unprecedented scale and faster access to hospital systems and clinical labs, improving penetration versus standalone sales and enabling broader rollout of screening programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeal announced: Nov 2025; close: early 2026\u003c\/li\u003e\n\u003cli\u003eAbbott diagnostics revenue: \u0026gt;$12B\/year\u003c\/li\u003e\n\u003cli\u003eGlobal reach: 160+ countries\u003c\/li\u003e\n\u003cli\u003eBenefit: faster hospital\/lab access, greater scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Health System Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExact Sciences partners with large integrated delivery networks (IDNs) and accountable care organizations to embed Cologuard and other diagnostics into population-health programs, making them the preferred first-line colorectal cancer screening at the institutional level.\u003c\/p\u003e\n\u003cp\u003eThese B2B deals drove renewed contracts covering over 30 million patients in 2024 and helped Exact Sciences report recurring diagnostic revenue of $1.8 billion in fiscal 2024, securing high-volume, predictable cash flow and simplifying care pathways for insured populations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIDN\/ACO embedment makes Cologuard default screening\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExact’s Cologuard scales: 1.3M kits, 68% compliance, $281M intl, Abbott deal to 160+ countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExact ships 1.3M+ Cologuard kits (2024), labs in Madison \u0026gt;2M test capacity, 68% compliance vs 38% FIT, international revenue $281M (14% of $2.01B) in 2024, IDN contracts cover \u0026gt;30M patients; Abbott deal Nov 2025 expands reach to 160+ countries and Abbott diagnostics \u0026gt;$12B yearly.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKits shipped (2024)\u003c\/td\u003e\n\u003ctd\u003e1.3M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab capacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;2M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard compliance\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$281M (14%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDN coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30M patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbbott diagnostics\u003c\/td\u003e\n\u003ctd\u003e$12B rev; 160+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eExact Sciences 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. You’re viewing the exact same editable and comprehensive Exact Sciences 4P's Marketing Mix analysis that’s fully complete and ready to use, not a sample or mockup. The file is high-quality and downloadable immediately upon checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750101168505,"sku":"exactsciences-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/exactsciences-marketing-mix.png?v=1772222075","url":"https:\/\/growthsharematrix.com\/products\/exactsciences-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}